Sarepta Therapeutics
SRPT
365 hedge funds and large institutions have $10.9B invested in Sarepta Therapeutics in 2019 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 127 increasing their positions, 115 reducing their positions, and 62 closing their positions.
160% more funds holding in top 10
Funds holding in top 10: 5 → 13 (+8)
28% more capital invested
Capital invested by funds: $8.48B → $10.9B (+$2.4B)
25% more call options, than puts
Call options by funds: $550M | Put options by funds: $440M
10% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 115
0.11% more ownership
Funds ownership: 96.48% → 96.59% (+0.11%)
5% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 62
2% less funds holding
Funds holding: 372 → 365 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$94.2M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$92.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$66.5M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$65.9M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$50.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$214M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$54.7M |
| 3 |
HCM
Highline Capital Management
New York
|
-$52M |
| 4 |
BlackRock
New York
|
-$32.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$31.1M |
SRPT Hedge Fund Activity: Q2 2019 in Review
365 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2019, worth a combined $10.9B — up 28% from $8.48B a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of SRPT and 59 opened new positions — a net loss of 3 holders — while 115 trimmed existing stakes and 127 added.
The largest buyer was First Trust Advisors, adding an estimated $94.2M. The largest seller was Fidelity Investments, cutting an estimated $214M.
- 365 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2019, down from 372 in Q1 2019.
- Funds reported $10.9B of Sarepta Therapeutics stock for Q2 2019, up 28% quarter-over-quarter.
- 59 funds opened new Sarepta Therapeutics positions in Q2 2019 and 62 closed out, a net change of -3 holders.
- The largest Sarepta Therapeutics buyer in Q2 2019 was First Trust Advisors, an estimated $94.2M added.
- The largest Sarepta Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $214M sold.
Based on aggregated 13F filings for Q2 2019.